Boston, Massachusetts 02111

  • resistant Ovarian Cancer

Purpose:

Afuresertib is an AKT inhibitor, a new class of agents under development that may provide physicians with a new clinical option to control platinum resistant ovarian cancer (PROC) progression. Afuresertib plus chemotherapy has demonstrated anti-tumor efficacy and an acceptable safety profile in patients with PROC in a published Phase I/II study. Therefore, the combination of afuresertib plus weekly paclitaxel could represent a clinically meaningful step forward in the clinical management of these difficult-to-treat patients with PROC.


Study summary:

A total of approximately 141 patients with PROC are planned to be enrolled and randomized with a 2:1 ratio in an open label manner to the 2 arms (94 patients in the combination treatment arm and 47 patients in the paclitaxel arm) for efficacy and safety evaluation. The randomization will be stratified by country: United States (US) vs China , duration of the platinum free interval (PFI): 1 3 months vs >3-6 months and number of prior platinum based therapy treatments (1/2 versus 3 prior platinum regimens). The study will consist of 3 periods. The first period is the Screening Period (Day -24 to -1) during which patients are screened for eligibility according to the inclusion and exclusion criteria. The second period is a Treatment Evaluation Period with a randomized, open-label, two arm parallel design (from starting study treatment until patients have progressive disease [PD], unacceptable toxicity, death, or withdrawal of consent). The PK study will be applied to both the combination treatment arm and control arm. The third period is a Follow up Period (safety evaluation at 30 days after the last dose of study treatment and OS and PFS follow up). Patients will be tested at baseline for phosphoinositide 3 kinase (PI3K)/AKT/PTEN pathway alterations, BRCA1/2 mutations and/or level of phospho AKT by IHC; the correlation of the efficacy endpoints and biomarker status will be analyzed retrospectively as an exploratory endpoint.


Criteria:

Inclusion Criteria: 1. Female patients at least 18 years of age at the time of signing the informed consent form and capable of giving written informed consent, which includes willingness to comply with the requirements and restrictions listed in the consent form. 2. Must provide informed consent for the procedures and the tests for PI3K/AKT/PTEN pathway alterations, BRCA1/2 mutations, and/or level of phospho-AKT. The archival tumor biopsy sample collected less than 1 year is preferred. If no archival tumor sample is available, fresh biopsy will be recommended. For patients who cannot provide a tumor sample or cannot accept fresh tumor biopsy, the Sponsor should be consulted about their qualification to enter this study. 3. Patients must have histologically or cytologically confirmed high grade serous OC, endometroid OC, or ovarian clear cell carcinoma (including fallopian tube and primary peritoneal cancers). Carcinosarcoma, sarcoma, mucinous OC, or low-grade serous histologies must be excluded. 4. Must not have previously received prior AKT or PI3K pathway or mTOR inhibitors. 5. Must have PROC (including fallopian tube and primary peritoneal carcinoma), defined as cancer progression between 1 month and 6 months after completion of prior platinum-based therapy (at least 4 cycles). Progression is defined by RECIST 1.1 criteria in association with symptoms necessitating treatment (Appendix 3). 6. The OC patients must have received 1 to 3 prior chemotherapies including no more than one chemotherapy after PROC was diagnosed. No other additional anticancer treatment is allowed except for PARP inhibitor or bevacizumab. Combination therapy with two or more drugs will be considered as one treatment, whereas maintenance therapy will be considered as continuation of the previous therapy. Patients should be appropriate candidates for treatment with single agent weekly paclitaxel based on investigator's clinical assessment. 7. Patients must either have received prior treatments with bevacizumab followed by disease progression, or bevacizumab cannot be used because of a specific contraindication, as listed (patients not treated with prior bevacizumab because of a contraindication may represent no more than 10% of the total number enrolled): - History of GI bleeding, ulceration, or fistula - Reversible Posterior Leukoencephalopathy Syndrome (RPLS) - Proteinuria - Infusion reaction - Any radiographic evidence of bowel (gastrointestinal tract) involvement - Hemorrhage: Grade 3-4 hemorrhage - Hypertension: hypertensive crisis or hypertensive encephalopathy - Arterial Thromboembolic Events: severe arterial thromboembolic events - Venous Thromboembolic Events: Grade 4 thromboembolic events 8. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1. 9. Must meet the following criteria for hematology parameters: - Absolute neutrophil count (ANC) ≥ 1,500/mm3 - Platelets ≥ 100,000/µL - Hemoglobin ≥ 9.0 g/dL 10. Total serum bilirubin ≤ 1.5 × upper limit of normal (ULN) (in patients with known Gilbert's syndrome, total bilirubin ≤ 3 × ULN with direct bilirubin ≤ 1.5 × ULN). 11. Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) must be < 2.5 × institutional ULN. For patients with liver metastasis, AST/ALT must be < 5.0 × institutional ULN. 12. Creatinine within 1.5 × ULN or creatinine clearance > 30 mL/min by Cockcroft Gault formula (Appendix 1). 13. Toxicities of prior therapy (except alopecia) should have been resolved to less than or equal to grade 1 as per NCI-CTCAE v5.0. 14. Patients must be able to tolerate oral medications and not have any GI illnesses that would preclude absorption of afuresertib. 15. Patient must have a life expectancy of greater than 6 months. 16. Must have at least one lesion that meets the definition of measurable disease by RECIST 1.1 criteria (Appendix 3). 17. Patients of childbearing potential must agree to use adequate contraception (barrier method of birth control or abstinence) prior to study entry and for the duration of study participation. If a woman becomes pregnant or suspects she is pregnant while participating in this study, she should inform her treating physician immediately. 18. Must be off strong inhibitors or inducers of CYP3A4/5 treatment for at least 2 weeks from Study Day 1. Exclusion Criteria: 1. Platinum refractory disease (progression during or less than 1 month of receiving previous platinum containing therapy). 2. Known or suspected brain metastases. 3. Receiving any other anticancer therapeutic agents other than study medicines. 4. Uncontrolled ascites. 5. Known symptomatic or impending cord compression, except if the patient has received definitive treatment for this and demonstrates evidence of clinically stable disease. 6. Presence of other active cancer within 3 years prior to enrollment (other than basal cell or squamous cell skin cancer, or any other cancer in situ currently in complete remission). 7. History of seizure or condition that may predispose to seizure that needs anti-epileptic medications; brain arteriovenous malformation; or intracranial masses, such as schwannomas and meningiomas that are causing edema or mass effect. 8. Known allergies, hypersensitivity, or intolerance to the excipients of afuresertib (for excipient information, refer to the IB17). 9. Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient (eg, compromise well-being) or that could prevent, limit, or confound the protocol-specified assessments. 10. Any medical contraindication to the use of paclitaxel. 11. Prior radiotherapy ≤ 15 days prior to Study Day 1, with the exception of a single fraction of radiotherapy for the purposes of palliation, which is permitted. 12. History of clinically significant ventricular arrhythmias (eg, ventricular tachycardia, ventricular fibrillation, or torsade de pointes). 13. Prolonged corrected QT interval by the Fridericia's correction formula (QTcF) on the screening ECG > 470 msec. Receiving concomitant medications known to prolong QTc, or which are associated with torsade de pointes, and are unable to discontinue use while receiving study drug. 14. History or evidence for any of the following: severe or unstable angina or myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (eg, pulmonary embolism, cerebrovascular accident including transient ischemic attacks) within 6 months prior to Study Day 1 or New York Heart Association Class III to IV heart disease. 15. Presence of uncontrolled hypertension (systolic blood pressure [BP] > 160 mmHg or diastolic BP > 100 mmHg). Patients with a history of hypertension are allowed, provided that BP is controlled to within these limits by anti-hypertensive treatment. 16. Human immunodeficiency virus (HIV)-positive patients with 1 or more of the following: 1. Not receiving highly active antiretroviral therapy 2. Receiving antiretroviral therapy that may interfere with the study drug (consult the Sponsor for review of medication prior to enrollment) 3. CD4 count < 350 based on a test within 3 months of the screening visit 4. An acquired immunodeficiency syndrome-defining opportunistic infection within 6 months of the start of screening 17. Had a major surgery ≤ 30 days prior to Study Day 1. 18. Presence of grade >2 neuropathy. 19. Prior receipt of chemotherapy, PARP inhibitor, bevacizumab, or investigational therapy within 28 days of enrollment or within 5 half lives of the agent, whichever is shorter. 20. Patients who are pregnant or lactating. 21. Patients with high risk of tuberculosis infection, based on investigator's clinical assessment, will be screened by tuberculosis screening test, such as the QuantiFERON® TB Gold In Tube test (QFT-GIT) or the T-SPOT®.TB test (T-Spot). 22. Patients with active hepatitis B (positive hepatitis B surface antigen [HBsAg] test at screening) or hepatitis C (positive hepatitis C virus [HCV] antibody test at screening) are not allowed to be enrolled in this study. Note: - Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as having a negative HBsAg test and a positive hepatitis B core antibody [HBcAb] test) are eligible. - Patients positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.


NCT ID:

NCT04374630


Primary Contact:

Yong Yue, MD
Phone: 17328502641
Email: yong.yue@laeknatp.com


Backup Contact:

Email: angela.castagna@laeknatp.com
Angela Castagna
Phone: 9085076807 ext. 9085076807


Location Contact:

Boston, Massachusetts 02111
United States



There is no listed contact information for this specific location.

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: September 15, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.